Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
Senseonics initiated a first-in-human early feasibility study of Freedom, an investigational one-year implantable CGM designed to communicate directly with a mobile device with no on-body transmitter. Freedom builds on the proven Eversense 365 sensing technology with an integrated battery and embedded Bluetooth; preclinical testing across roughly seven weeks and more than 18,500 communication data points showed 100% communication success for the preferred design.
Key figures
- Drug Name
- Freedom (transmitter-free one-year CGM system)
- Phase Of Trial
- first-in-human / early feasibility
- Potential launch
- 2028
- Pivotal study target
- 2027
- Preclinical data points
- 18,500+
- Preclinical communication success
- 100% within target distance
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.